Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
RégulationOne-OffSanté et médecineEurope2mois
FutuurVérifier la disponibilitéDonnées de résolution vérifiéesProbabilité implicite actuelle
Non 89%
Non 89%Qualité du marché
33 / 100
Faible qualitéVolume 24h
—
Liquidité
1,2 k €
Faible liquiditéTraders
4
Commentaires
0
Données du marché
Mis à jour il y a 2 minutes
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsBy 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
Manifold MarketsEpstein-Barr virus vaccine by 2032?
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsUK social media ban in effect by which date?
PolymarketRègles
If, at any point between January 1st, 2026, 00h00 UTC, and December 31st, 2026, 25H59 UTC, the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), or the European Commission authorizes the use or sale of a therapy whose primary mechanism is directly editing the patient's genomic DNA, for any human condition other than sickle cell disease and beta thalassemia, this market will resolve to "Yes".
- Otherwise, it will resolve to "No".
- The Primary Designated Source is the official approval database of whichever regulator is involved — FDA Drug Approvals (fda.gov), MHRA product information (gov.uk/mhra), or the European Commission Union Register of medicinal products (ec.europa.eu/health/documents/community-register).
- Approvals of new indications, formulations, or labels for therapies already approved for sickle cell disease or beta thalassemia (e.g., exa-cel / Casgevy expansions) do not count; only therapies addressing a different human condition.
- Conditional, accelerated, or emergency authorizations from the named regulators docount for this market’s purposes.
- Therapy mechanisms that do not directly edit the patient's genomic DNA in vivo or ex vivo (e.g., mRNA therapies, gene replacement via AAV without genomic editing) do not count.
